- Trials with a EudraCT protocol (29)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
29 result(s) found for: Basket Cell.
Displaying page 1 of 2.
| EudraCT Number: 2019-001879-37 | Sponsor Protocol Number: GB1275-1101(KEYNOTE-A36) | Start Date*: 2020-01-14 |
| Sponsor Name:GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc. | ||
| Full Title: A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination... | ||
| Medical condition: Phase 1: Advanced solid tumors, metastatic pancreatic adenocarcinoma Phase 2: Specified metastatic solid tumors | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-003385-84 | Sponsor Protocol Number: GO40782(RXDX-101-02) | Start Date*: 2016-03-15 | ||||||||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltf | ||||||||||||||||||
| Full Title: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRA... | ||||||||||||||||||
| Medical condition: Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) DE (Ongoing) ES (Ongoing) NL (Ongoing) PL (Ongoing) IT (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-006386-38 | Sponsor Protocol Number: 20210104 | Start Date*: 2022-06-02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Amgen, Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE 301) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: CZ (Ongoing) ES (Temporarily Halted) AT (Ongoing) IT (Ongoing) HU (Ongoing) BE (Ongoing) NL (Ongoing) PT (Ongoing) DK (Ongoing) FI (Completed) BG (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-003026-69 | Sponsor Protocol Number: IO102-IO103-022 | Start Date*: 2022-05-09 | |||||||||||||||||||||
| Sponsor Name:IO Biotech ApS | |||||||||||||||||||||||
| Full Title: A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung ... | |||||||||||||||||||||||
| Medical condition: Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-003546-16 | Sponsor Protocol Number: Debio1143-106 | Start Date*: 2019-03-06 |
| Sponsor Name:Debiopharm International SA | ||
| Full Title: SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial A dose-optimization, exploratory phase Ib/II study to assess... | ||
| Medical condition: Solid Tumors | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-005591-35 | Sponsor Protocol Number: INCMOR0208-101 | Start Date*: 2021-06-30 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti-CD19 Monoclonal Antibody Tafasitamab and the PI3K delta Inhibito... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Ongoing) IT (Ongoing) ES (Temporarily Halted) AT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-002489-34 | Sponsor Protocol Number: AV-APL-B-002-22 | Start Date*: 2023-02-09 | |||||||||||
| Sponsor Name:Pharma Mar, S.A. | |||||||||||||
| Full Title: A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromi... | |||||||||||||
| Medical condition: Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) IT (Ongoing) FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003839-33 | Sponsor Protocol Number: UC-GMP/1908 | Start Date*: 2020-05-18 | |||||||||||
| Sponsor Name:UNICANCER | |||||||||||||
| Full Title: Phase II basket trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma | |||||||||||||
| Medical condition: Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, cervix, lung, anal, vulva, and penile. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-005108-89 | Sponsor Protocol Number: VHIO17002 | Start Date*: 2019-01-25 | |||||||||||
| Sponsor Name:Vall d’Hebron Institute of Oncology (VHIO) | |||||||||||||
| Full Title: Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors. | |||||||||||||
| Medical condition: Subjects with advanced solid tumor | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) SE (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004873-29 | Sponsor Protocol Number: SGNTUC-019 | Start Date*: 2021-05-31 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Seagen Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) PL (Completed) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-004450-36 | Sponsor Protocol Number: MK-2140-006 | Start Date*: 2022-06-10 | ||||||||||||||||||||||||||
| Sponsor Name:Merck Sharp & DohmeLLC | ||||||||||||||||||||||||||||
| Full Title: A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (... | ||||||||||||||||||||||||||||
| Medical condition: Aggressive and Indolent B-cell Malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) EE (Ongoing) ES (Ongoing) PL (Trial now transitioned) CZ (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) IT (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-001757-54 | Sponsor Protocol Number: APL-101-01 | Start Date*: 2020-11-24 | ||||||||||||||||
| Sponsor Name:Apollomics, Inc. | ||||||||||||||||||
| Full Title: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulat... | ||||||||||||||||||
| Medical condition: Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) FI (Ongoing) HU (Suspended by CA) IT (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2013-004810-16 | Sponsor Protocol Number: TPU-TAS-120-101 | Start Date*: 2014-04-10 | |||||||||||
| Sponsor Name:Taiho Oncology Inc | |||||||||||||
| Full Title: PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS | |||||||||||||
| Medical condition: Advanced solid tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) NL (Ongoing) PT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004383-25 | Sponsor Protocol Number: CDFF332A12101 | Start Date*: 2021-10-22 | |||||||||||
| Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
| Full Title: A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2alp... | |||||||||||||
| Medical condition: Advanced, relapsed Clear Cell Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) CZ (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000269-30 | Sponsor Protocol Number: MO29518 | Start Date*: 2015-08-26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressed following at least one line of prior systemic anticancer therapy, or ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) NL (Completed) IE (Completed) AT (Completed) ES (Completed) FI (Completed) GB (Completed) DK (Completed) PL (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-002103-19 | Sponsor Protocol Number: CTL-002-001 | Start Date*: 2020-12-16 | |||||||||||
| Sponsor Name:CatalYm GmbH | |||||||||||||
| Full Title: A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjec... | |||||||||||||
| Medical condition: Advance-stage, relapsed/refractory solid tumors in non-curable state, that relapsed post or were refractory to a prior anti-PD-1/PD-L1 therapy. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002766-14 | Sponsor Protocol Number: 2020-3093 | Start Date*: 2020-10-26 |
| Sponsor Name:Gustave Roussy | ||
| Full Title: An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors | ||
| Medical condition: Patients with DNA repair-deficient or platinum-sensitive solid tumors | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003406-47 | Sponsor Protocol Number: FS118-21201 | Start Date*: 2023-01-31 | |||||||||||
| Sponsor Name:invoX Pharma Limited | |||||||||||||
| Full Title: A Phase 2 Open-Label Basket Study of FS118, a LAG-3/PD-L1 Bispecific Antibody, in Subjects with Advanced and Early-Stage Malignancies | |||||||||||||
| Medical condition: Advanced and early-stage malignancies | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001009-56 | Sponsor Protocol Number: MK-7684A-005 | Start Date*: 2021-10-12 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Se... | |||||||||||||
| Medical condition: Advanced solid tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003115-21 | Sponsor Protocol Number: 2018/2798 | Start Date*: 2019-02-19 | |||||||||||||||||||||||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||||||||||||||||||||||
| Full Title: A phase II whole exoMe sequencing-bAsed baskeT trIal for combination therapy with durvaLumab (anti-PDL1) (MEDI4736) anD tremelimumAb (anti-CTLA4) in patients with metastatic solid tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma a... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
